Byoung-Joo Seo

Dr. Byoung-Joo Seo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Amina KhatunAmina Khatun
Amina Khatun
SPSun You Park
Sun You Park
NSNadeem Shabir
Nadeem Shabir
Salik NazkiSalik Nazki
Salik Nazki
AKA-Rum Kang
A-Rum Kang
WKWon-Il Kim
Won-Il Kim
DiNap [(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one], an analog of a natural product (the chalcone flavokawain), was synthesized and characterized in this study. Porcine reproductive and respiratory syndrome virus (PRRSV) is the most challenging threat to the swine industry worldwide. Currently, commercially available vaccines are ineffective for controlling porcine reproductive and respiratory syndrome (PRRS) in pigs. Therefore, a pharmacological intervention may represent an alternative control measure for PRRSV infection. Hence, the present study evaluated the effects of DiNap on the replication of VR2332 (a prototype strain of type 2 PRRSV). Initially, in vitro antiviral assays against VR2332 were performed in MARC-145 cells and porcine alveolar macrophages (PAMs). Following this, a pilot study was conducted in a pig model to demonstrate the effects of DiNap following VR2332 infection. DiNap inhibited VR2332 replication in both cell lines in a dose-dependent manner, and viral growth was completely suppressed at concentrations ≥0.06 mM, without significant cytotoxicity. Consistent with these findings, in the pig study, DiNap also reduced viral loads in the serum and lungs and enhanced the weight gain of pigs following VR2332 infection, as indicated by comparison of the DiNap-treated groups to the untreated control (NC) group. In addition, DiNap-treated pigs had fewer gross and microscopic lesions in their lungs than NC pigs. Notably, virus transmission was also delayed by approximately 1 week in uninfected contact pigs within the same group after treatment with DiNap. Taken together, these results suggest that DiNap has potential anti-PRRSV activity and could be useful as a prophylactic or post-exposure treatment drug to control PRRSV infection in pigs.

16 December 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
GPGyeong-Seo Park
Gyeong-Seo Park
HKHwan-Ju Kim
Hwan-Ju Kim
MCMyung A. Cho
Myung A. Cho
SKSeung-Chai Kim
Seung-Chai Kim
CJChang-Gi Jeong
Chang-Gi Jeong
BSByoung-Joo Seo
Byoung-Joo Seo
Introduction: Shiga toxin-producing Escherichia coli (STEC), particularly strains harboring Stx2e , are the primary cause of edema disease (ED) in swine, leading to acute mortality and economic loss. Despite the use of antimicrobials and autogenous vaccines, control remains inadequate due to high genetic variability and upregulated multidrug resistance (MDR). In Korea, field outbreaks persist in post-weaning pigs, underscoring the need for immunologically relevant vaccine candidates. This study aimed to characterize STEC isolates from 2014 to 2025 and identify representative strains for vaccine development through integrated molecular, phenotypic, and resistance profiling. Methods: A total of 184 STEC isolates were collected from clinical swine cases submitted between 2014 and 2025. Isolates were characterized via PCR-based virulence gene profiling, cytotoxicity assays using Vero cells, antimicrobial susceptibility testing, and Gompertz-modeled in vitro growth kinetics. Principal component analysis (PCA) and multivariate clustering were applied to assess phenotypic patterns. Two candidate vaccine strains were selected using an integrated scoring system incorporating virulence, cytotoxicity, metabolic fitness, and antimicrobial resistance profiles. Results: A total of 184 STEC isolates were recovered from swine diagnostic submissions across nine Korean provinces between 2014 and 2025. Genotypic analysis identified 29 virulence gene profiles, with Stx2e and F18 being predominant. Phenotypic assays revealed that Stx2e-only isolates exhibited superior growth kinetics and higher cytotoxicity than other genotypes. Antimicrobial susceptibility testing demonstrated widespread multidrug resistance, especially to sulfonamides, β -lactams, and aminoglycosides. Principal component analysis showed clustering based on toxin profiles and metabolic traits. No non-MDR isolates were observed, underscoring the high resistance burden. Two Stx2e-positive isolates with complementary F18 profiles, strong proliferation (>4.0 × 10 8 CFU/mL), and consistent cytotoxicity were selected as optimal vaccine candidates. Whole-genome sequencing confirmed their genetic stability and field relevance, supporting their advancement into vaccine development pipelines. Conclusion: This study provides a decade-long surveillance-based framework for rational STEC vaccine design in swine. Two Stx2e-positive strains were selected as representative immunogen candidates based on integrated genotypic and phenotypic criteria. These findings support the development of scalable, field-relevant vaccine platforms aimed at reducing antimicrobial use and controlling edema disease in Korean pig populations.

28 August 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
GPGyeong-Seo Park
Gyeong-Seo Park
SLSomin Lee
Somin Lee
MJMin A Jeong
Min A Jeong
SLSo Young Lee
So Young Lee
DCDong-Geun Cho
Dong-Geun Cho
CKChonghan Kim
Chonghan Kim
Caseous lymphadenitis (CLA) is a chronic and subclinical bacterial disease of ruminants caused by Corynebacterium pseudotuberculosis (C. pseudotuberculosis) infection. Until 2014, there were no reports of CLA outbreaks in South Korea; however, the prevalence of CLA cases has steadily increased. In this study, we used recently obtained field isolates to develop the first inactivated CLA vaccine in South Korea and evaluated it in various animal models. The inactivated vaccine was evaluated for virulence and effectiveness. Mice were tested for virulence and immunization challenges, and guinea pigs and Korean Native Black Goats (KNBGs) evaluated various vaccine concentrations to determine the optimal dose and effectiveness. In the case of KNBGs, clinical symptoms were not observed after vaccination. In addition, CLA-specific IgG was detected at a significantly (p < 0.05) high level and was maintained. In histopathological evaluations, inflammation was predominantly observed in the prefemoral lymph nodes in the non-vaccinated+CHAL group. The genetic diversity of C. pseudotuberculosis, which has become widespread in South Korea, is less than 0.5% our vaccine is expected to prevent infection by a wide range of strains effectively. In summary, our CLA vaccine can potentially prevent CLA and foster the growth of South Korea’s domestic KNBG industry.

19 June 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
GPGyeong-Seo Park
Gyeong-Seo Park
BSByoung-Joo Seo
Byoung-Joo Seo
WKWooju Kwon
Wooju Kwon
YSYEONG LEE SEOK
YEONG LEE SEOK
HLHyo Jeong Lee
Hyo Jeong Lee
CKChonghan Kim
Chonghan Kim
Background/Objectives: Porcine circovirus type 2d (PCV2d) is the predominant genotype associated with porcine circovirus-associated disease (PCVAD), leading to significant economic losses. In South Korea, current vaccine lot-release testing relies on a T/C-ratio-based guinea pig assay, which lacks scientific justification and methodological robustness. This study aimed to develop and validate a statistically defined in-house ELISA using rabbit-derived polyclonal antibodies against PCV2d for the standardized evaluation of immunogenicity. Methods: Polyclonal IgG was generated by immunizing a rabbit with inactivated PCV2d, and it was purified through Protein A chromatography. Guinea pigs (n = 18) were immunized with IMMUNIS® DMVac, an inactivated PCV2d vaccine candidate developed by WOOGENE B&G, at different doses. In-house ELISA parameters were optimized (antigen coating, blocking agent, and substrate incubation), and analytical performance was evaluated by ROC, linearity, reproducibility, and specificity. Sera from guinea pigs and pigs were analyzed under validated conditions. Results: The optimal performance was achieved using 105 genomic copies/mL of the antigen coating and a 5% BSA blocking agent. The assay showed strong diagnostic accuracy (AUC = 0.97), reproducibility (CVs < 5%), and linearity (R2 = 0.9890). Specificity tests with PCV2a, PCV2b, and PRRSV showed minimal cross-reactivity (<7%). The cross-species comparison revealed a positive correlation (R2 = 0.1815) and acceptable agreement (bias = −0.21) between guinea pig and porcine sera. The validated cut-off (S/P = 0.4) enabled accurate classification across both species and aligned well with commercial kits. Conclusions: The in-house ELISA offers a robust, reproducible, and scientifically validated platform for immunogenicity verification, supporting its application in Korea’s national lot-release system. Homologous competition assays with PCV2d are planned to further confirm antigen specificity.

13 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
GPGyeong-Seo Park
Gyeong-Seo Park
MPMinsung Park
Minsung Park
SLSomin Lee
Somin Lee
CKChonghan Kim
Chonghan Kim
BSByoung-Joo Seo
Byoung-Joo Seo
Bovine neonatal diarrhea (BND) is a leading cause of morbidity and mortality in pre-weaned calves. Commercial maternal vaccines targeting bovine rotavirus (BRV), bovine coronavirus (BCoV), and enterotoxigenic Escherichia coli (ETEC) have been available for decades, yet field outbreaks continue in vaccinated herds. This review examined peer-reviewed literature published between January 2019 and March 2026, identified through a structured PubMed search supplemented by reference-list screening. For BRV, a field strain sharing its VP7 genotype with a vaccine component was not neutralized by vaccine-induced antiserum, indicating that genotype concordance does not predict serologic coverage. For BCoV, hemagglutinin-esterase variation and regional lineage divergence indicate surface-protein evolution, although data linking these changes to reduced efficacy are not available. For ETEC, adhesin diversity and antimicrobial resistance affect both vaccination strategy and case management. Maternal vaccination retains biological value, but field performance is constrained by colostral variability, incomplete passive transfer, and product-to-product immunogenic differences. For all three pathogens, antigenic divergence from vaccine strains is located at individual epitopes, receptor-binding domains, or adhesins rather than at the level of whole-pathogen identity. Subunit and multi-epitope antigen designs, for which proof-of-concept constructs have been reported, operate at this level, and their selection requires characterization of candidate antigens for efficacy, diversity, polymorphism, and cross-protective breadth. Such antigen improvements address the pathogen-side gap but not the passive-transfer and mucosal constraints. Functional surveillance to guide antigen updating, field trials that measure passive-transfer efficiency, and adjunctive strategies are identified as priorities for BND control.

12 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
GPGyeong-Seo Park
Gyeong-Seo Park
SLSomin Lee
Somin Lee
MPMinsung Park
Minsung Park
MKMINSEOK KIM
MINSEOK KIM
ELEunhui Lee
Eunhui Lee
BSByoung-Joo Seo
Byoung-Joo Seo
Background/Objectives: Caseous lymphadenitis (CLA), caused by Corynebacterium pseudotuberculosis, is difficult to control on goat farms because of subclinical infection, abscess rupture, environmental contamination, and repeated herd-level exposure. This study evaluated a Korean inactivated CLA vaccine under commercial goat farm conditions and combined vaccination outcomes with farm-level bacteriological profiling. Methods: Goats from three commercial farms were allocated according to baseline CLA serostatus and vaccination status into seropositive vaccinated, seronegative vaccinated, seropositive non-vaccinated, and seronegative non-vaccinated control groups. Vaccinated goats received two intramuscular doses at weeks 0 and 4. Clinical signs, external abscess occurrence, growth performance, CLA-specific antibody responses, and abscess bacterial loads were monitored. Farm-level microbial profiles were assessed using culture, MALDI-TOF MS, and targeted PCR. Results: Baseline antibody classification showed strong agreement between the commercial CLA ELISA and the in-house whole-bacterial IgG ELISA, with a Spearman’s rho of 0.89 (p < 0.001) and 96.7% classification agreement. Vaccination induced CLA-specific antibody responses in both assays and was not associated with a persistent reduction in growth performance. External abscesses were observed only in baseline seropositive goats. Abscesses occurred in 1/30 vaccinated and 2/15 non-vaccinated seropositive goats, but the difference was not statistically significant (p = 0.254). Microbial profiling showed farm-dependent detection patterns. Conclusions: The vaccine induced CLA-specific antibody responses (immunogenicity) with acceptable tolerability. The exploratory abscess endpoint was underpowered, and clinical protection was not confirmed; larger studies are needed.